<DOC>
	<DOCNO>NCT00612989</DOCNO>
	<brief_summary>Primary objective To determine maxi tolerate dose Temodar® combo w O6-benzylguanine administer 5 consecutive day pts w progressive/recurrent GBM To characterize toxicity associate w Temodar® combo w O6-BG administer 5 consecutive day pts w progressive/recurrent GBM To determine Neulasta®-supported MTD define MTD Temodar® combo O6-BG administer 5 day receive Neulasta® per treatment cycle day 7 &amp; 14 pt w progressive/recurrent GBM To obtain preliminary response rate Temodar® combo w O6-BG administer 5 consecutive day pts w progressive/recurrent GBM</brief_summary>
	<brief_title>Ph I 5-day Temozolomide + O6-BG Treatment Pts w Recurrent / Progressive GBM</brief_title>
	<detailed_description>1 primary objective determine maximum tolerate dose Temodar combo w O6-benzylguanine administer 5 consecutive day pts w progressive/recurrent GBM . Another primary objective characterize toxicity associate w Temozolomide combo w O6-BG administer 5 consecutive day pts w progressive/recurrent GBM . 3rd primary objective determine Neulasta-supported MTD define MTD Temozolomide combo w O6-BG administer 5 day receive Neulasta per treatment cycle day 7 &amp; 14 pt w progressive/recurrent GBM . Secondary objective obtain preliminary response rate Temodar combo w O6-BG administer 5 consecutive day pts w progressive/recurrent GBM . Population Glioblastoma . O6-BG Administration : O6-BG 120mg/m2 administer intravenously 1 hr follow continuous infusion O6-BG 30mg/m2/day 5 consecutive day . Every 48hrs repeat dose 120mg/m2 1hr administer total 3 dos . Temodar Administration : Temodar administer orally , fast state within 60 min end 1st 1-hr infusion O6-BG &amp; every 24 hr continuous infusion O6-BG . Temozolomide administer day 1 treatment cycle every 24 hr thereafter 5 day w treatment cycle repeat every 28 day . Body surface area calculate begin cycle use calculate daily dose Temozolomide administered cycle . Neulasta Administration . Neulasta administer subcutaneous injection 0.6mL pre-filled syringe contain 6mg pegfilgrastim . It administer per chemotherapy cycle day 7 &amp; 14 . Neulasta administer period 14 day &amp; 24hrs administration cytotoxic chemo include Temozolomide . Data Analysis conduct Biostatistics department Duke .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>Pts histologically proven supratentorial GBM Pts recurrent/progressive MG . If pt receive stereotactic radiosurgery / brachytherapy part prior therapy , histologic confirmation recurrence/metabolic image consistent w recurrent tumor recommend mandate There must measurable disease contrastenhanced magnetic resonance imaging study / CT scan perform &lt; 2wks study drug administration Interval &gt; 12 wks completion XRT &amp; enrollment protocol Interval &gt; 4 wks prior chemo &amp; enrollment protocol unless unequivocal evidence tumor progression Interval &gt; 2 wks prior surgical resection &amp; enrollment protocol unless unequivocal evidence tumor progression Age &gt; 18 yr KPS &gt; 70 percent Following baseline study require &lt; 1wk study drug administration : serum creatinine &lt; 1.5 x ULN &amp; Hematologic Status Following baseline study require &lt; 1wk study drug administration : absolute neutrophil count &gt; 2000 cells/microliter ; platelet count &gt; 125,000 cells/microliter Following baseline study require &lt; 1 wk study drug administration : serum SGOT &amp; total bilirubin &lt; 2.5 x ULN Signed informed consent , approve IRB , obtain prior initiate treatment Pts w Reproductive Potential : Pts must agree practice effective birth control measure study &amp; 2 month complete therapy Pregnant/breast feeding women/ women/men w reproductive potential practicing adequate contraception . Therapy may associate w potential toxicity fetus/child exceeds mini risk necessary meet health need mother Prior treatment w O6BG + Temozolomide combo Active infection require intravenous antibiotic Known diagnosis HIV infection Pts w history another primary malignancy currently clinically significant/currently require active intervention Pts unwilling/unable comply w protocol due serious medical/psychiatric condition Pts receive investigational drug &lt; 2 wks prior start study drug/have recover side effect therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>GBM</keyword>
	<keyword>Temodar</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>O6-BG</keyword>
	<keyword>O6-Benzylguanine</keyword>
	<keyword>Recurrent GBM</keyword>
	<keyword>Progressive GBM</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Malignant glioma</keyword>
	<keyword>Neulasta</keyword>
	<keyword>Pegfilgrastim</keyword>
</DOC>